首页> 外国专利> Antibody (disintegrin and metalloproteinase ADAM17 (- 17) and their use for the treatment of cancer

Antibody (disintegrin and metalloproteinase ADAM17 (- 17) and their use for the treatment of cancer

机译:抗体(整合素和金属蛋白酶ADAM17(-17)及其在治疗癌症中的用途

摘要

This refers to an Antibody capable of binding to ADAM17, and moreover, the amino acid and Nucleic Acid sequences encoding Said Antibody. In One aspect, relates to an Antibody or Antigen binding Fragments capable of binding to ADAM17 with Antitumor Activity. Also includes the use of this Antibody as a drug for the treatment of cancer.Finally, includes compositions comprising Said Antibody, alone or in combination with other compounds or Conjugation against cancer, and use these for the treatment of cancer.Claim 1: a monoclonal antibody or its Fragments of Union of Antigen Epitope, which binds even ADAM17 and Inhibits the diffusion of at least a substrate of ADAM17, wherein Said epitope of ADAM17 is an epitope within the next domain Mo Membrane (PDM) sequence of the sec. ID no. 32.
机译:这是指能够与ADAM17结合的抗体,此外,还指与编码所述抗体的氨基酸和核酸序列结合的抗体。一方面,涉及能够结合具有抗肿瘤活性的ADAM17的抗体或抗原结合片段。还包括该抗体作为治疗癌症的药物的用途。最后,包括单独或与其他化合物或结合物结合使用的包含所述抗体的组合物,并将其用于治疗癌症。权利要求1:单克隆抗体抗体或其抗原表位联合的片段,其甚至结合ADAM17并抑制ADAM17的至少底物的扩散,其中所述ADAM17的表位是sec的下一个域Mo膜(PDM)序列内的表位。证件号码。 32。

著录项

  • 公开/公告号AR098953A1

    专利类型

  • 公开/公告日2016-06-22

    原文格式PDF

  • 申请/专利权人 PIERRE FABRE MEDICAMENT;

    申请/专利号AR2014P104902

  • 发明设计人

    申请日2014-12-23

  • 分类号C07K16/40;A01K67/027;A61K39/395;A61P35;C07K16/28;C12N5/10;

  • 国家 AR

  • 入库时间 2022-08-21 14:27:37

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号